Has Elna Saah received payments from drug or device companies?

Yes. Drug and device makers reported $27,067 in general payments to Elna Saah across 42 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Elna Saah did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Elna Saah come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Elna Saah

Hematology & Oncology · Birmingham, ALNPI 1316042617

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $18,388 of the $27,067 with a category attached, or 67.9%. 14 manufacturers reported payments, led by Novo Nordisk at 39.6% of the total. 2025 is the largest year on record at $10,738, more than ten times the $329 reported in 2019.

$27,067in general payments, 2019–2025

Across 42 payments — averaging $644.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$11K
Pfizer$5K
Global Blood Therapeutics, Inc.$5K
Vertex$3K
Novartis$2K
Agios Pharmaceuticals, Inc.$428
plus $616 from 8 others

$1,207,682in research payments, 2019–2025

Across 22 payments — averaging $54,895 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Novartis$797K
Novo Nordisk AS$236K
Novo Nordisk Health Care AG$98K
Global Blood Therapeutics, Inc.$43K
Agios Pharmaceuticals, Inc.$33K

What the payments were for

Consulting fees$18,38868%
Speaking & faculty fees$3,51513%
Travel & lodging$2,91911%
Food & beverage$2,2458%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	8	$10,712
Pfizer	8	$5,332
Global Blood Therapeutics, Inc.	4	$4,514
Vertex	1	$3,395
Novartis	4	$2,070
Agios Pharmaceuticals, Inc.	6	$428
Emmaus Medical, Inc.	2	$154
Servier Pharmaceuticals LLC	2	$150
Terumo BCT, Inc.	1	$103
United Therapeutics Corporation	1	$69
Genentech USA, Inc.	2	$68
Jazz Pharmaceuticals Inc.	1	$27
Sobi, Inc	1	$24
Medunik USA Inc.	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,067 in reported general payments places this provider in the 80th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama →

Other hematology & oncology in Birmingham

Amitkumar MehtaBirmingham$683K
Pankit VachhaniBirmingham$545K
Luciano CostaBirmingham$409K
Khaleel AshrafBirmingham$379K
Michael BirrerBirmingham$302K
Rudolph NavariBirmingham$254K
Mayur NarkhedeBirmingham$193K
Midhun MallaBirmingham$144K
Robert ConryBirmingham$143K
David MooneyBirmingham$120K

See the full list for Alabama →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →